Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angioplasty, Balloon | 2 | 2016 | 58 | 1.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2016 | 282 | 1.000 |
Why?
|
| Aortic Aneurysm | 2 | 2016 | 84 | 0.900 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2016 | 211 | 0.880 |
Why?
|
| Stents | 3 | 2016 | 459 | 0.860 |
Why?
|
| Carotid Stenosis | 2 | 2019 | 105 | 0.750 |
Why?
|
| Aortography | 2 | 2016 | 54 | 0.630 |
Why?
|
| Femoral Artery | 2 | 2016 | 94 | 0.550 |
Why?
|
| Vena Cava, Superior | 1 | 2016 | 9 | 0.550 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2016 | 8 | 0.550 |
Why?
|
| Nurse Anesthetists | 1 | 2016 | 2 | 0.540 |
Why?
|
| Hepatic Artery | 1 | 2016 | 22 | 0.530 |
Why?
|
| Anesthesiologists | 1 | 2016 | 18 | 0.530 |
Why?
|
| Limb Salvage | 1 | 2016 | 68 | 0.520 |
Why?
|
| Aneurysm, Ruptured | 1 | 2016 | 72 | 0.500 |
Why?
|
| Informed Consent | 2 | 2015 | 133 | 0.500 |
Why?
|
| Aorta | 1 | 2016 | 106 | 0.490 |
Why?
|
| Phlebotomy | 1 | 2015 | 8 | 0.480 |
Why?
|
| Suction | 1 | 2015 | 31 | 0.480 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 46 | 0.480 |
Why?
|
| Government Regulation | 1 | 2015 | 44 | 0.470 |
Why?
|
| Hemorrhage | 1 | 2016 | 272 | 0.470 |
Why?
|
| Postoperative Care | 1 | 2015 | 114 | 0.460 |
Why?
|
| Needles | 1 | 2015 | 66 | 0.460 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 158 | 0.460 |
Why?
|
| Aneurysm, Infected | 1 | 2014 | 11 | 0.450 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 158 | 0.450 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 329 | 0.440 |
Why?
|
| Thrombosis | 1 | 2016 | 190 | 0.440 |
Why?
|
| Aneurysm, False | 1 | 2014 | 46 | 0.430 |
Why?
|
| Escherichia coli Infections | 1 | 2014 | 87 | 0.430 |
Why?
|
| Ethics Committees, Research | 2 | 2003 | 34 | 0.400 |
Why?
|
| Communication | 1 | 2017 | 558 | 0.390 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 1481 | 0.370 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 579 | 0.350 |
Why?
|
| Humans | 24 | 2019 | 60165 | 0.320 |
Why?
|
| Cautery | 1 | 2008 | 1 | 0.320 |
Why?
|
| Nails | 1 | 2008 | 39 | 0.300 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 66 | 0.300 |
Why?
|
| Hematoma | 1 | 2008 | 74 | 0.300 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 581 | 0.290 |
Why?
|
| Spinal Puncture | 1 | 2007 | 13 | 0.280 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2007 | 30 | 0.270 |
Why?
|
| Constriction, Pathologic | 2 | 2016 | 111 | 0.260 |
Why?
|
| General Surgery | 1 | 2008 | 193 | 0.260 |
Why?
|
| Treatment Outcome | 4 | 2016 | 5267 | 0.240 |
Why?
|
| Prosthesis Design | 2 | 2016 | 211 | 0.230 |
Why?
|
| Hemodilution | 1 | 2004 | 12 | 0.230 |
Why?
|
| Physician's Role | 1 | 2005 | 120 | 0.230 |
Why?
|
| Dalteparin | 1 | 2003 | 3 | 0.220 |
Why?
|
| Nitrous Oxide | 1 | 2003 | 9 | 0.220 |
Why?
|
| Therapeutic Human Experimentation | 1 | 2003 | 5 | 0.220 |
Why?
|
| Oxidoreductases | 1 | 2003 | 65 | 0.220 |
Why?
|
| Physicians | 1 | 2008 | 442 | 0.210 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2004 | 113 | 0.210 |
Why?
|
| Pressure Ulcer | 1 | 2003 | 37 | 0.210 |
Why?
|
| Tobacco Use Disorder | 1 | 2005 | 245 | 0.210 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 107 | 0.200 |
Why?
|
| Human Experimentation | 1 | 2002 | 33 | 0.200 |
Why?
|
| Ischemia | 2 | 2019 | 195 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2004 | 253 | 0.180 |
Why?
|
| Smoking Cessation | 1 | 2005 | 538 | 0.170 |
Why?
|
| Vascular Surgical Procedures | 1 | 2002 | 245 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2003 | 489 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 443 | 0.160 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2002 | 224 | 0.160 |
Why?
|
| Microsurgery | 1 | 2019 | 52 | 0.150 |
Why?
|
| Vascular Patency | 2 | 2016 | 132 | 0.140 |
Why?
|
| Phlebography | 1 | 2016 | 44 | 0.140 |
Why?
|
| Popliteal Artery | 1 | 2016 | 25 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2016 | 115 | 0.130 |
Why?
|
| Multiple Organ Failure | 1 | 2016 | 43 | 0.130 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2016 | 132 | 0.130 |
Why?
|
| Iliac Artery | 1 | 2016 | 46 | 0.130 |
Why?
|
| Anesthesiology | 1 | 2016 | 43 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 116 | 0.130 |
Why?
|
| Vacuum | 1 | 2015 | 8 | 0.120 |
Why?
|
| Biomarkers | 1 | 2019 | 1215 | 0.110 |
Why?
|
| Embolization, Therapeutic | 1 | 2016 | 309 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1036 | 0.100 |
Why?
|
| Aged | 3 | 2016 | 13601 | 0.100 |
Why?
|
| Disease Progression | 1 | 2016 | 1054 | 0.100 |
Why?
|
| Middle Aged | 3 | 2016 | 16554 | 0.080 |
Why?
|
| Computers | 1 | 2008 | 48 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 735 | 0.070 |
Why?
|
| Male | 3 | 2016 | 27985 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2008 | 306 | 0.060 |
Why?
|
| Software | 1 | 2008 | 376 | 0.060 |
Why?
|
| Female | 3 | 2016 | 31256 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2004 | 59 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 568 | 0.060 |
Why?
|
| Group Practice | 1 | 2004 | 12 | 0.060 |
Why?
|
| 5,10-Methylenetetrahydrofolate Reductase (FADH2) | 1 | 2003 | 1 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2003 | 18 | 0.060 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2003 | 21 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2004 | 44 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 71 | 0.050 |
Why?
|
| Blood Circulation | 1 | 2003 | 9 | 0.050 |
Why?
|
| United States | 2 | 2008 | 7623 | 0.050 |
Why?
|
| Physical Examination | 1 | 2003 | 103 | 0.050 |
Why?
|
| Universities | 1 | 2004 | 152 | 0.050 |
Why?
|
| Warfarin | 1 | 2003 | 110 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2003 | 177 | 0.050 |
Why?
|
| Paris | 1 | 2002 | 4 | 0.050 |
Why?
|
| Ethics, Medical | 1 | 2002 | 38 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 303 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2002 | 230 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2002 | 186 | 0.040 |
Why?
|
| Research Design | 1 | 2003 | 569 | 0.040 |
Why?
|
| Age Factors | 1 | 2002 | 1527 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 5205 | 0.020 |
Why?
|
| Life Tables | 1 | 2002 | 24 | 0.010 |
Why?
|
| Polytetrafluoroethylene | 1 | 2002 | 18 | 0.010 |
Why?
|
| Prosthesis-Related Infections | 1 | 2002 | 33 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2002 | 6150 | 0.010 |
Why?
|